Asthma: Causes, Triggers, and Types

Asthma is a chronic inflammatory disease of the airways affecting an estimated 25 million people in the United States, according to the CDC National Asthma Control Program. Understanding its underlying mechanisms, recognized trigger categories, and clinical subtypes is essential for accurate diagnosis and appropriate management. This page covers the pathophysiology of asthma, the environmental and physiological factors that provoke episodes, the major classification systems used by clinicians, and the boundaries that separate asthma from related airway conditions. For a broader orientation to lung disease categories and pulmonary care, the pulmonary health overview provides foundational context.

Definition and Scope

Asthma is defined by the National Heart, Lung, and Blood Institute (NHLBI) as a chronic lung disease characterized by three overlapping physiological processes: airway inflammation, bronchospasm (transient narrowing of the bronchial tubes), and airway hyperresponsiveness — an exaggerated constriction response to stimuli that would not affect a healthy airway. A fourth feature, mucus hypersecretion, contributes to airflow obstruction during acute episodes.

The condition is classified as obstructive rather than restrictive. Spirometric testing typically reveals a reduced FEV₁/FVC ratio (the ratio of forced expiratory volume in one second to forced vital capacity), with significant reversibility — defined by the Global Initiative for Asthma (GINA) as an improvement of at least 12% and 200 mL in FEV₁ following bronchodilator administration. This reversibility distinguishes asthma from fixed obstructive conditions such as COPD.

The CDC estimates asthma accounts for approximately 1.6 million emergency department visits annually in the US (CDC FastStats: Asthma). The disease burden falls disproportionately on children, Black Americans, and individuals in lower-income households, patterns documented in the NHLBI 2020 Focused Updates to the Asthma Management Guidelines.

How It Works

The Inflammatory Cascade

Asthma pathophysiology begins with sensitization. In allergic (atopic) asthma — the most common subtype — exposure to an allergen triggers immunoglobulin E (IgE)-mediated activation of mast cells and eosinophils in the bronchial mucosa. This releases histamine, leukotrienes, and prostaglandins, producing the characteristic triad of bronchospasm, mucosal edema, and increased mucus secretion.

In non-allergic asthma, the inflammatory pathway bypasses IgE and involves innate immune activation, often through viral respiratory infections, irritant exposure, or cold air. Both pathways converge on airway smooth muscle contraction and epithelial damage, which, over time, can lead to structural airway remodeling — a process associated with permanent loss of lung function in poorly controlled disease.

Airway Remodeling

Chronic, inadequately treated inflammation promotes subepithelial fibrosis, smooth muscle hypertrophy, and increased vascularity. GINA guidelines identify airway remodeling as a driver of the fixed obstruction component sometimes observed in long-standing asthma, reinforcing the clinical importance of anti-inflammatory — not just bronchodilator — therapy. The management strategies for limiting this progression are discussed in detail on the managing asthma page.

Common Scenarios

Recognized Trigger Categories

Asthma triggers fall into four broad categories:

  1. Allergens — house dust mites, cockroach allergen, mold spores, pet dander, and seasonal pollens. The National Institute of Allergy and Infectious Diseases (NIAID) identifies indoor allergen exposure as a primary driver of pediatric asthma exacerbations.
  2. Irritants and Air Pollutants — tobacco smoke, ozone, particulate matter (PM₂.₅), nitrogen dioxide, and occupational dusts or fumes. EPA standards under the Clean Air Act (42 U.S.C. § 7401 et seq.) set National Ambient Air Quality Standards (NAAQS) for six criteria pollutants, several of which are established asthma triggers. The relationship between air quality and respiratory health is explored further on the air quality and lung health page.
  3. Respiratory Infections — rhinovirus is the pathogen most consistently associated with asthma exacerbations across all age groups, per NHLBI documentation.
  4. Exercise and Physical Conditions — exercise-induced bronchoconstriction (EIB) occurs in approximately 40–90% of individuals with asthma (NHLBI 2020 Guidelines); cold, dry air amplifies this response.

Additional triggers include aspirin and NSAID sensitivity (affecting roughly 10–20% of adults with asthma), gastroesophageal reflux disease (GERD), and emotional stress.

Clinical Presentations

Asthma symptoms — recurrent wheeze, chest tightness, cough (particularly nocturnal), and dyspnea — frequently overlap with those of other conditions. Symptoms such as wheezing and chest tightness require evaluation to confirm an asthma diagnosis versus alternative causes. Occupational exposures can produce a distinct presentation; approximately 15% of adult-onset asthma cases are attributable to workplace exposures according to the American College of Chest Physicians (CHEST), a category addressed under occupational lung disease.

Decision Boundaries

Major Classification Systems

By allergic phenotype:
- Allergic (atopic) asthma — IgE-mediated, onset typically in childhood, frequently accompanied by eczema or allergic rhinitis.
- Non-allergic asthma — normal serum IgE, often adult-onset, may be driven by aspirin sensitivity, obesity, or exercise.

By severity (NHLBI / GINA framework):

Severity Level Daytime Symptoms Nighttime Symptoms FEV₁ (% predicted)
Intermittent ≤2 days/week ≤2 nights/month ≥80%
Mild Persistent >2 days/week 3–4 nights/month ≥80%
Moderate Persistent Daily >1 night/week 60–80%
Severe Persistent Continuous Frequent <60%

By endotype (biologic subtype):
GINA and NHLBI increasingly distinguish T2-high asthma (eosinophilic, IL-4/IL-13 pathway dominant) from T2-low asthma (neutrophilic or paucigranulocytic). This distinction has direct therapeutic implications: biologic agents such as monoclonal antibodies targeting IL-5, IL-4Rα, or IgE are approved by the FDA specifically for severe T2-high eosinophilic asthma.

The reversibility criterion separates most asthma from COPD, but overlap exists in older adults and long-term smokers — a pattern GINA and GOLD jointly term Asthma-COPD Overlap (ACO). Vocal cord dysfunction (VCD/PVFM) mimics asthma with inspiratory stridor but shows normal spirometry and flow-volume loop abnormalities at the laryngeal level. Pulmonary function testing, including the full suite of pulmonary function tests, remains central to establishing these diagnostic boundaries.

The regulatory and clinical infrastructure governing asthma diagnosis and care — including Medicare/Medicaid reimbursement codes, OSHA respiratory protection standards, and FDA drug approval frameworks — is outlined at regulatory context for pulmonary.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)